BTXA™ IS DEEMED SAFE, WELL TOLERATED AND REACHED GOOD SATISFACTORY LEVELS
WHY BTXATM
QUALITY GUARANTEE
PRODUCT EFFICACY
Efficacy and Tolerability Study of BTXA™ Treatment in Patients with Facial Wrinkles
An open-label, prospective, multicenter and multidisciplinary phase III study was carried out in Brazil. 110 patients with facial wrinkles were being studied continuously for 180 days.
HIGH SATISFACTORY RATE : 98% of Patients Satisfied after BTXA treatment
Injection Result During the Follow Up Visits
FAST ONSET - Satisfactory rate reach up to 94% in 14 days after injection
LONG LASTING - 50% patients maintained satisfactory result up to 6 months
Reference
- Costa J, Rieder C, et al. A double-blind, randomised, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007; 30:39-42
- Drug Safety Report-Prosigne® (Botulinum Toxin Type A), Jan 2009, Hughs. Data on file
- 2007 American Society of Aesthetic Plastic Surgery (ASAPS) Cosmetic Surgery National Data Bank Statistics.
- Talarico S, Bgatin E, Pecora CS, Ferreira LM, Orofino R, Godoy A, et al. Open-label, prospective, multicenter, multidisciplinary Phase III Study to evaluate the efficacy and tolerability of Prosigne® (Botulinum Toxin Type A) in the aesthetic treatment of the upper third of the face in patients with facial wrinkles. Data on file.